ArticleBMC urology2025
Urinary function, sexual function and quality of life after prostate low-dose-rate brachytherapy: a retrospective analysis.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is most commonly diagnosed at a localized stage, allowing the majority of patients to receive curative treatment. The prognosis is often favorable, and there are numerous treatment options available, emphasizing the importance of assessing the side effects associated with each treatment. Low-dose-rate (LDR) brachytherapy is one such treatment option, supported by robust evidence regarding its efficacy and side effects. However, most published data primarily rely on physician-assessed toxicity, which may underestimate the patient's experience of side effects. This study aims to provide a comprehensive overview of the urinary side effects of LDR brachytherapy, with a focus on patient-reported outcomes.
methodsThis retrospective study included 199 patients treated with LDR-brachytherapy years 2000-2012 at Helsinki University Hospital. Questionnaires used to assess urinary toxicity were International Prostate Symptom Score (IPSS) and The Danish Prostatic Symptom Score (DAN-PSS). Additionally, sexual function was assessed using the International Index of Erectile Function (IIEF) questionnaire. Urinary function was assessed with flowmetry, reporting peak flow rate and postvoid residual measurement.
resultsThere was a deterioration in urinary function during the first six months post-procedure, as evidenced by a decline in the urinary function questionnaires and uroflowmetry measurements. For most patients, this deterioration was transient, with median symptom scores returning to baseline after one year. A slight discrepancy was observed between patient-reported outcome measures and urinary function assessed by flowmetry.
conclusionsLDR brachytherapy is a well-tolerated treatment for localized prostate cancer. While many patients experience acute side effects that subside relatively quickly, there is a small risk of prolonged side effects. This risk should be thoroughly discussed with patients when making treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.